AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00575887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
Study NCT04035915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited driving pressure
Description: Keep driving pressure \<15 cmH2O
Study NCT04035915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional mechanical ventilation strategies
Description: Keep tidalvolume \</= 8
Study NCT02016703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythritol drink
Study NCT04443270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate
Description: Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days.
Study NCT01528488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVOZAC Calming Skin Spray
Description: EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
Study NCT01528488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
Study NCT02016703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo drink
Study NCT01271062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass surgery
Study NCT01271062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal surgery
Study NCT01271062 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: very low caloric diet
Study NCT01658072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-Articular Injection
Description: Use of a different analgesic protocol, based on a peri-articular injection
Study NCT01658072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Patient Controlled Analgesia (Epidural PCA)
Description: Epidural analgesia pathway.
Study NCT03013478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment As Usual (TAU)
Description: Treatment normally offered at this primary care clinic
Study NCT03013478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT4CBT program
Study NCT01092104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652
Description: TBR-652 25 mg
Study NCT01092104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TBR-652 Matching Placebo
Description: Matching Placebo
Study NCT01092104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652 50 mg
Description: TBR-652 50 mg QD for 10 days
Study NCT01092104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652 75 mg
Description: TBR-652 75 mg QD for 10 days
Study NCT01092104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652 100 mg
Description: TBR-652 100 mg QD for 10 days
Study NCT01092104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBR-652 150 mg
Description: TBR-652 150 mg QD for 10 days
Study NCT01709162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01709162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Study NCT00929318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Study NCT04334694 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Atrial flow regulator (Occlutech® AFR device)
Description: Atrial septostomy followed by implantation of AFR.
Study NCT03122288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Cognitive Training
Description: These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
Study NCT03122288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No-Contact Control
Description: This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
Study NCT00447993 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low Dose NT-501
Description: Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery
Study NCT00447993 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High Dose NT-501
Description: High Dose NT-501 Implanted in study eye and fellow eye received sham surgery
Study NCT04292665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical Massage
Description: During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
Study NCT04292665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benson Relaxation Exercise
Description: During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
Study NCT04292665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients will continue to receive standard nursing care and no further intervention will be made during the research.
Study NCT02546466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Star-shape taping (SFT)
Description: For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
Study NCT02546466 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Functional Taping (Sham-FT)
Description: For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
Study NCT02546466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention Strategy (MIS)
Description: The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
Study NCT02111928 — intervention group
Intervention type: DEVICE
Intervention: NovaTears® Eye Drops
Description: Topical eye drops for lubrication of the ocular surface
Study NCT01269333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: omeprazole 20mg for 7 days
Study NCT01269333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvoxamine
Description: fluvoxamine 50mg for 7 days
Study NCT01269333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 7 days
Study NCT04201886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: serum calprotectin
Description: serum calcium binding leucocyte protein
Study NCT02476240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parkinson's disease Sensory Attention Focused Exercise
Description: The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
Study NCT02476240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parkinson's disease Sensory Attention Focused Exercise
Description: The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
Study NCT02249130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV)
Study NCT02249130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Study NCT02249130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV)
Study NCT02249130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Study NCT02249130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Study NCT02249130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T)
Study NCT02702661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block (FICB)
Description: Fascia Iliaca Compartment Block
Study NCT02702661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anaesthetic Infiltration (LAI)
Description: Local Anaesthetic Infiltration (LAI) of the portal tracts
Study NCT02702661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine 0.125% - 40ml
Study NCT02702661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Levobupivacaine 0.125% - 40ml
Study NCT02185053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPC-201
Study NCT01464931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Adminstered by subcutaneous injection
Study NCT03040557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible footwear
Description: - Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
Study NCT03040557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthopedic insole
Description: - Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
Study NCT04708548 — intervention group
Intervention type: OTHER
Intervention: Health-related Quality of Life
Description: Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.
Study NCT04708548 — intervention group
Intervention type: OTHER
Intervention: Psychological Distress
Description: Measured of the distress experienced by patients
Study NCT04708548 — intervention group
Intervention type: OTHER
Intervention: Fatigue
Description: Measure of the extreme tiredness resulting from mental or physical exertion or illness
Study NCT04708548 — intervention group
Intervention type: OTHER
Intervention: Cognitive Functioning
Description: Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.
Study NCT03838510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REBOOT
Description: The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
Study NCT00233324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen with target saturation of 85 to 89%
Description: Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
Study NCT02475746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
Study NCT02475746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Interacting drug which will be given 200 mg QD for 8 days in period 2
Study NCT01701557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slow fluid rate
Description: 10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
Study NCT01701557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fast fluid rate
Description: 20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
Study NCT02496611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss with pharmacotherapy
Description: Participants randomized to the drug intervention group will receive Exenatide extended-release.
Study NCT02496611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss without pharmacotherapy
Description: Participants randomized to the placebo group will receive a placebo.
Study NCT02551978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The serious game KOP
Description: The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
Study NCT02445092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washing the insemination catheter with sperm washing media
Description: Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~* Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~* Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~* Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter.
Study NCT03798483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised exercise
Description: The intervention will be comprised of up to 6, one-to-one physiotherapy sessions, over a maximum duration of 3 months. 1 or 2 extra sessions are allowed if deemed essential by the participant's physiotherapist. Less than 6 physiotherapy sessions can be agreed with the participant if they have achieved their goals. Throughout this time participants will be required to perform an exercise programme a minimum of 3 times per week. The exercise programme aims to increase leg muscle strength and facilitate a return to the participant's usual activities. It may include hopping and change of direction tasks if these are activities the participant would normally do. Behavioural change techniques to increase participant adherence to the exercise programme will also be used.
Study NCT02289417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Study NCT02289417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Study NCT02289417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01749397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Given IP
Study NCT01749397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01749397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02036775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan tablet
Description: One Lasolvan tablet 30 mg twice daily for 5 days.
Study NCT02036775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan effervescent tablet
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Study NCT02036775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan prolonged-release hard capsule
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Study NCT02036775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan prolonged-released capsules
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Study NCT03521466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
Study NCT00835965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 5 mg administered intravenously following endotracheal intubation
Study NCT00835965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
Study NCT00835965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
Study NCT02094560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP7.1
Description: CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
Study NCT02763449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoing
Description: Participants will self-monitor their physical activity level via activity monitors
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h